SecBot SecBot
8-K ·Filed Jun 26, 2026

ATRA

Atara Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001193125-26-285498
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The interim CFO appointment is a temporary measure; monitor for search for a permanent CFO and any further executive departures. The CAO departure is not a red flag alone, but the lack of a permanent CFO may indicate organizational instability typical of a micro-cap biotech.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.17
T+0 close · Jun 26, 2026 · via day close
Latest settled
−20.05%
T+60 · $8.93
Vs SPY
−24.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $11.17entry
  2. T+1 · 5mo ago +2.78%α +2.00% · $11.48
  3. T+5 · 4mo ago −2.60%α −3.98% · $10.88
  4. T+20 · 4mo ago −29.27%α −29.00% · $7.90
  5. T+60 · 8w ago −20.05%α −24.44% · $8.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO via a consulting agreement with Charles River CFO, Inc. The filing is a routine officer change and carries no material financial information.

Key Facts

  • Chief Accounting Officer Yanina Grant-Huerta notified of employment end effective July 17, 2026.
  • Kevin G. Sarney appointed interim CFO, principal financial officer, and principal accounting officer on June 26, 2026.
  • Sarney, age 61, is a CPA with 25+ years of life science finance experience, serving via a consulting agreement with Charles River CFO, Inc. at an hourly rate.
  • No compensation directly to Sarney; consulting agreement can be terminated with 30 days' notice.
  • No family relationships or related-party transactions between Sarney and the company.

Financial Impact

No direct financial impact; hourly consulting fees are not disclosed.

Risk Factors

  • Prolonged interim CFO arrangement could signal difficulty attracting permanent finance leadership.
  • Further executive departures or financial control weaknesses may emerge.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-285498
Document: 0001193125-26-285498-index-headers.html0001193125-26-285498
Document: 0001193125-26-285498-index.html0001193125-26-285498
Document: 0001193125-26-285498.txt0001193125-26-285498

Track record

11 reports on ATRA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
  3. Jun 26, 202620w ago 8-K Neutral 3/10 Viewing Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
  4. Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
  5. May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  6. May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
  8. Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
  9. Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
  10. Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026